578 related articles for article (PubMed ID: 21358697)
21. SGLT2 inhibition--a novel strategy for diabetes treatment.
Chao EC; Henry RR
Nat Rev Drug Discov; 2010 Jul; 9(7):551-9. PubMed ID: 20508640
[TBL] [Abstract][Full Text] [Related]
22. Sodium-glucose cotransporter inhibitors for diabetes.
Isaji M
Curr Opin Investig Drugs; 2007 Apr; 8(4):285-92. PubMed ID: 17458177
[TBL] [Abstract][Full Text] [Related]
23. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.
Cangoz S; Chang YY; Chempakaseril SJ; Guduru RC; Huynh LM; John JS; John ST; Joseph ME; Judge R; Kimmey R; Kudratov K; Lee PJ; Madhani IC; Shim PJ; Singh S; Singh S; Ruchalski C; Raffa RB
J Clin Pharm Ther; 2013 Oct; 38(5):350-9. PubMed ID: 23909868
[TBL] [Abstract][Full Text] [Related]
24. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
[TBL] [Abstract][Full Text] [Related]
25. SGLT2 inhibitors.
Dardi I; Kouvatsos T; Jabbour SA
Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
[TBL] [Abstract][Full Text] [Related]
26. Empagliflozin in the treatment of type 2 diabetes: evidence to date.
Shubrook JH; Bokaie BB; Adkins SE
Drug Des Devel Ther; 2015; 9():5793-803. PubMed ID: 26586935
[TBL] [Abstract][Full Text] [Related]
27. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
Morillas C
Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
[TBL] [Abstract][Full Text] [Related]
28. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Cariou B; Charbonnel B
Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus.
Tejedor Jorge A
Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224
[TBL] [Abstract][Full Text] [Related]
30. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Arch Pharm Res; 2016 Feb; 39(2):259-270. PubMed ID: 26450351
[TBL] [Abstract][Full Text] [Related]
31. SGLT2 inhibitors in the treatment of type 2 diabetes.
Hasan FM; Alsahli M; Gerich JE
Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
[TBL] [Abstract][Full Text] [Related]
32. Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics.
Ho LT; Kulkarni SS; Lee JC
Curr Top Med Chem; 2011; 11(12):1476-512. PubMed ID: 21510836
[TBL] [Abstract][Full Text] [Related]
33. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
[TBL] [Abstract][Full Text] [Related]
34. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
35. Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy.
Bhardwaj G; Vakani M; Srivastava A; Patel D; Pappachan A; Murumkar P; Shah H; Shah R; Gupta S
Arch Biochem Biophys; 2021 Oct; 710():108995. PubMed ID: 34289381
[TBL] [Abstract][Full Text] [Related]
36. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
[TBL] [Abstract][Full Text] [Related]
37. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Dominguez Rieg JA; Rieg T
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):43-52. PubMed ID: 31081587
[TBL] [Abstract][Full Text] [Related]
38. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
39. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
[TBL] [Abstract][Full Text] [Related]
40. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
Sano M
J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
